openPR Logo
Press release

Polymyositis Market Size in the 7MM was ~USD 114 million in 2023, estimated DelveInsight

12-03-2024 07:08 PM CET | Health & Medicine

Press release from: ABNewswire

Polymyositis Market Size in the 7MM was ~USD 114 million in 2023,

DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover Key Insights into the Polymyositis Market with DelveInsight's In-Depth Report @ Polymyositis Market Size [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Polymyositis Market Report

* In December 2024:- Cabaletta Bio- Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, and IMNM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
* In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
* Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
* Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
* The DelveInsight analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.
* The Polymyositis Companies such as Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
* Promising Polymyositis Therapies such as Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous , and others.

Stay ahead in the Polymyositis Therapeutics Market with DelveInsight's Strategic Report @ Polymyositis Market Outlook [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polymyositis Epidemiology Segmentation in the 7MM

* Total Polymyositis Diagnosed Prevalent Cases
* Polymyositis Gender-specific Diagnosed Prevalent Cases
* Polymyositis Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Prevalence [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polymyositis Emerging Drugs

* SAPHNELO (Anifrolumab): AstraZeneca

SAPHNELO (anifrolumab) is a first-in-class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity.

* Dazukibart (PF-06823859): Pfizer

The drug dazukibart (PF-06823859) is being developed to treat moderate to severe dermatomyositis and Polymyositis by Pfizer along with other indications like systemic lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). Neutralizing antibodies against humanized immunoglobulin and a new biological entity (NBE) make up the therapeutic candidate. It works by specifically targeting interferon beta 1 (IFNB1) and is injected intravenously and subcutaneously.

Polymyositis Market Outlook

Polymyositis is an inflammatory muscle disease that requires a multifaceted approach to treatment, primarily focusing on reducing inflammation, managing symptoms, and preventing long-term complications. The mainstay of treatment is corticosteroids, such as prednisone, which are often administered as the first line of therapy due to their potent anti-inflammatory effects. These steroids are typically prescribed in high doses initially and gradually tapered based on the patient's response. For patients who do not respond adequately to corticosteroids or who experience significant side effects, immunosuppressive agents such as methotrexate or azathioprine are commonly used. These medications help to modulate the immune system and can be used as steroid-sparing agents to reduce the dependency on corticosteroids.

Get In-Depth Knowledge on Polymyositis Market Trends and Forecasts with DelveInsight @ Polymyositis Treatment Market [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Polymyositis Market Report

* Coverage- 7MM
* Polymyositis Companies- Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
* Polymyositis Therapies- Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.
* Polymyositis Therapeutic Assessment: Polymyositis Current marketed and Polymyositis Emerging Therapies
* Polymyositis Market Dynamics: Polymyositis Market drivers and Polymyositis Market Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Polymyositis Market Report @ Polymyositis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Polymyositis Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary

7 Disease Background and Overview

8 Epidemiology and Patient Population of Polymyositis

9 Patient Journey

10 Emerging Therapies

11 Polymyositis: Seven Major Market Analysis

12 KOL Views

13 SWOT Analysis

14 Unmet needs

15 Market Access and Reimbursement

16 Appendix

17 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

18 Bibliography

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polymyositis-market-size-in-the-7mm-was-usd-114-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Polymyositis Market Size in the 7MM was ~USD 114 million in 2023, estimated DelveInsight here

News-ID: 3769492 • Views:

More Releases from ABNewswire

Taty Fittipaldi Featured at OD Network 2025 Conference With Workshop on Story-Driven Leadership
Taty Fittipaldi Featured at OD Network 2025 Conference With Workshop on Story-Dr …
Taty Fittipaldi, executive coach and author of 'Mastering Business Storytelling,' led a virtual session on using business storytelling to align, inspire, and drive action during the OD Network 2025 Conference. Leadership strategist and executive coach Taty Fittipaldi led a high-impact virtual workshop during the OD Network 2025 Conference, hosted in partnership with Gonzaga University's School of Leadership Studies, delivering insights on how business storytelling can drive alignment, connection, and strategic action
Real Estate Listing Agents in Litchfield Park, AZ Reveal Strategy Behind Minimal Price Reductions That Boost Home Visibility
Real Estate Listing Agents in Litchfield Park, AZ Reveal Strategy Behind Minimal …
Litchfield Park, AZ - During a recent listing appointment, a homeowner posed a question that The Caren Team realized many sellers might be wondering: "What's with those $1 or $100 price reductions on homes listed for hundreds of thousands of dollars?" While these minimal adjustments may seem insignificant at first glance, they serve strategic purposes that can dramatically impact a home's visibility in today's digital marketplace. Matt Caren, a seasoned real
Ibrahim & Ibrahim Law Firm Recognized as a Top-Rated Divorce Lawyer in Jersey City, New Jersey
Ibrahim & Ibrahim Law Firm Recognized as a Top-Rated Divorce Lawyer in Jersey Ci …
Ibrahim & Ibrahim Law Firm, a leading family law practice based in Jersey City, New Jersey, has been recognized as one of the top-rated divorce law firms in the area. Known for its compassionate approach and strong record of success, the firm specializes in all aspects of divorce and family law. Jersey City, NJ - Ibrahim & Ibrahim Law Firm, a leading name in Jersey City family law [https://www.google.com/maps?cid=14607464839494053987], has been
Asia Forex Mentor Announces 2025 Broker Awards Recognizing Trader-Preferred Firms Across Finance
Asia Forex Mentor Announces 2025 Broker Awards Recognizing Trader-Preferred Firm …
Unlike typical industry rankings driven by ad spend or insider votes, the Asia Forex Mentor Broker Awards are shaped by the trading community itself - with nominations and votes coming directly from active traders, and final decisions reviewed by a panel of respected finance experts. SINGAPORE - October 06, 2025 - Asia Forex Mentor (AFM), a global leader in trader education and financial insights, has officially opened nominations for the 2025

All 5 Releases


More Releases for Polymyositis

Polymyositis Market on Track for Major Expansion by 2034, According to DelveInsi …
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Polymyositis
Polymyositis Market Outlook 2025-2034: Trends, Growth, and Forecast Analysis
Polymyositis (PM) is a rare, chronic autoimmune disease that causes muscle weakness and inflammation. It affects the muscles responsible for movement, leading to significant disability and a reduction in quality of life. As the understanding of autoimmune diseases expands and new therapeutic options emerge, the polymyositis market is experiencing significant growth. This article explores the key drivers, market trends, challenges, and growth opportunities in the polymyositis market, projected to expand
Polymyositis Clinical Pipeline | 7+ Innovators Pushing the Boundaries of Treatme …
The Polymyositis market is advancing with groundbreaking research and innovative therapeutic developments. DelveInsight's 'Polymyositis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Polymyositis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Polymyositis pipeline domain. For Polymyositis emerging drugs, the Polymyositis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product
Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Polymyositis Pipeline Insight 2024" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Polymyositis Research. Learn more about our innovative pipeline
Polymyositis Treatment Market Size Research Report 2024
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Polymyositis Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Polymyositis Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Polymyositis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Polymyositis market size from 2019 to 2032, segmented